quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:39:19·44d
ANALYSTRating
Ocugen Inc. logo

Oppenheimer initiated coverage on Ocugen with a new price target

OCGN· Ocugen Inc.
Health Care
Original source

Companies

  • OCGN
    Ocugen Inc.
    Health Care

Recent analyst ratings

  • Mar 17UpdateCanaccord Genuity$12.00
  • Mar 11UpdateOppenheimer$10.00
  • Oct 15UpdateMaxim Group$4.00
  • Mar 1UpdateChardan Capital Markets$3.50
  • Aug 23UpdateMizuho$5.00
  • Jun 15UpdateROTH Capital$8.00

Related

  • PR1d
    Ocugen to Present at April 2026 Investor and Industry Conferences
  • SEC3d
    SEC Form PRER14A filed by Ocugen Inc.
  • SEC6d
    SEC Form PRE 14A filed by Ocugen Inc.
  • SEC9d
    SEC Form SCHEDULE 13G filed by Ocugen Inc.
  • PR14d
    Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
  • INSIDER21d
    SEC Form 4 filed by Zhang Junge
  • PR23d
    Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Ocugen Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022